Nanox, an Israeli corporation that has developed the first solid state digital X-ray source designed to be used in real-world medical imaging applications, has partnered with Shamir Medical Center in Tzifrin to launch a pilot program to provide 3D imaging of COVID-19 patients. The Nanox.ARC advanced-imaging system would enable rapid indication of patients with worsening pneumonia as a result of COVID-19.
“This could be a game-changer for COVID patients who do not have access to more expensive machines,” said Shamir CEO Prof. Osnat Lev Zion Korach.
Shamir revealed that it had the system in November – the first hospital in the world to have in-house access to the Nanox.ARC. Nanox presented the Nanox.ARC at the 2021 Radiology Society of North America Annual Meeting from a clinical setting, broadcast from Shamir Medical Center (Assaf Harofeh). Shamir is working with Nanox to complete clinical development and research of the system. The goal, according to the company, would be to have Nanox.ARC in use on the market in a brief time.
“We have a very strong radiology department and Nanox is collaborating with them to do more research – to compare the resolution and quality of the pictures and exams taken by Nanox.ARC to regular or other CT scans,” Lev Zion Korach explained.
Nanox. ARC’s use of digital source energy X-rays allows the formation of a previously unattainable data snapshot, which includes 3-D digital imaging results (as opposed to 2-D results), allowing for a more detailed diagnosis that until now was only available through expensive CT scans.
The solid-state digital X-ray source has a low level of radiation meaning there is no need for a big X-ray room with a complex setup to use Nanox.ARC. Nanox’s Korean subsidiary is expected to start commercial pilot production early 2022 of the silicon MEMs chip, which is integral to the Nanox digital X-ray source.
“It’s high-resolution, cheaper and involves less radiation,” Lev Zion Korach said. “That’s what makes it a game-changer.”
X-ray imaging devices are critical for diagnosing lung conditions that occur in patients suffering from severe COVIDNanox-19. However, only around a third of the world’s population has access to proper imaging services or has to wait a considerable amount of time to use them – something that could mean life or death with the virus.
This is specifically the case in Third World and poorer areas, like Africa. Already, Nanox has signed an agreement with Eileeno Pharma Ltd. to produce 1,000 devices in Africa, upon completion of development and obtaining the relevant certification.
Nanox has also finalized the MSaaS (Master as a Software Service Agreement) agreement with International Clinics Group, a medical equipment distributor which serves public & private hospitals, health systems, military hospitals, and medical centers in Chile, Bolivia, and Peru, for the deployment of 350 Nanox.ARC units. As of date, the Company entered into MSaaS agreements for deployment of 6,500 Nanox.ARC units.
Nanox recently completed the merger with NANO-X AI LTD (formerly Zebra Medical Vision LTD, “Nanox AI”), a deep-learning medical imaging analytics company, in an all-stock deal valued at approximately $110 million at closing, with up to $84 million in contingent consideration to be paid in additional stock if Nanox AI enters into any of two designated commercial agreements and achieve certain milestones. Additionally, the Company completed the acquisition of USARAD Holdings, Inc., a leading provider of teleradiology services, and the assets of MDWEB, LLC., a decentralized marketplace connecting imaging facilities with radiologists, together, for approximately $7.3 million in cash and $12.9 million in stock, with up to $2.0 million in cash and up to $8.0 million in stock in deferred consideration upon the completion of various milestones.
Nanox AI secured its 8th FDA 510(k) clearance for its Coronary Artery Calcium (“CAC”) solution as part of its population health offering. CAC is an important biomarker in determining the risk of coronary disease. The CAC solution is expected to empower clinicians to report findings and recommend preventative treatments before a coronary event occurs, which has the potential to save lives while lowering costs for the healthcare systems. Nanox AI’s mission is helping to diagnose populations at scale with its AI-based solutions, enabling IDNs and commercial payers to detect and treat patients at risk for chronic conditions while accurately adjusting their covered population risk.
Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Ran Poliakine founded Powermat, the company that pioneered wireless charging. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, visit www.nanox.vision.
Using patient imaging data already available to the healthcare system, proprietary algorithms highlight early, previously undetected signs of common chronic diseases. The newly discovered findings can then initiate a further medical assessment to establish individual preventative care pathways for patients.
Itzhak Maayan, Nanox Imaging: IR AT nanox.vision
Source: Jpost Dec 2, 2021
About JLM- BioCity
News on the many life science and healthcare companies in the Jerusalem area can be seen at https://jlm-biocity.org/jlm-biocity-innovations/
JLM-BioCity is a non-profit organization focused on developing and excelling Jerusalem’s bio-community.
We invite you, researcher, professional, investor and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.
If you want your Company featured in our blogs , news releases, please contact: info at jlm-biocity.org